论文部分内容阅读
目的 研究美喘清、地塞米松对支气管哮喘小儿β受体和cAMP水平的影响。方法 采用放射配基受体结合分析方法，对支气管哮喘急性发作期患儿应用单一口服美喘清以及美瑞清和静注地塞米松联合治疗前后外周血淋巴细胞β－AR和血浆cAMP水平及临床治疗效果进行了观察。结果美喘清组：β－AR治疗前为3911．9±306．9site／cell，治疗后为2672．8±343．7site／cell（P＜0．01）；cAMP治疗前为18．9±1．gpm／mL，治疗后为19.6±1．5pm／mL（P＞0．05）；美喘清＋地塞米松组：β－AR治疗前为4018．8±344．5site／cell，治疗后为2227．9±208．2site／cell（P＜0．01）；cAMP治疗前为17．4±1．5pm／mL，治疗后为21．3±2．1pm／mL（P＞0．05）。结论美喘清在体内激活了β-AR，对哮喘急性发作期治疗有效，而联合用药时，静注地塞米松未见明显加强美喘清激活β-AR的作用。
Objective To study the effects of MeiChuanQing and dexamethasone on β -receptor and cAMP levels in children with bronchial asthma. Methods Radioligand receptor binding assay was used to detect the levels of β-AR and cAMP in peripheral blood lymphocytes of patients with bronchial asthma exacerbation after single oral administration of mechrystatin and combination of deoxymethasone and dexamethasone. The therapeutic effect was observed. The results of mechryng group: β-AR before treatment was 3911.9 ± 306.9site / cell, after treatment was 2672.8 ± 343.7site / cell (P <0.01); cAMP before treatment was 18.9 ± 1. gpm / mL after treatment was 19.6 ± 1.5pm / mL (P> 0.05); Meichuanqing + dexamethasone group: 4018.8 ± 344.5site / cell before β-AR treatment, 2227.9 ± 208.2site / cell (P <0.01), 17.4 ± 1.5pm / mL before cAMP treatment and 21.3 ± 2.1pm / mL after treatment (P> 0.05) . Conclusion MeiChuanQing activated β-AR in vivo, which is effective in the treatment of acute exacerbation of asthma. However, the combination of mechrymycin and dexamethasone did not significantly enhance the effect of melatonin-activated β-AR.